Therapeutic yield of an NGS pan-cancer panel utilizing joint AMP/ASCO/CAP classification guidelines.

e13513Background: Treating tumors with therapies that target specific molecular aberrations is the hallmark of personalized medicine. Genomic sequencing can provide information to guide these choices and recent guidelines have been published to establish consistency of cancer variant classification. Methods: We performed retrospective analysis of 62 solid tumor cases to assess the yield of reported FDA therapies, investigational drug trials and overall classification profile of the JAX ActionSeq™ test (targeted panel of 212 cancer related genes). Actionability was based on the joint AMP/ASCO/CAP variant interpretation guidelines, which included 3 reportable tiers; 2 clinically significant (Tier I, Tier II) and 1 clinical significance unknown (Tier III). Benign/likely benign variants (Tier IV) were not reported. Results: In total, 331 variants were reported [Avg: 5.3 per patient (pt)] with mean target coverage 1037x. Clinically significant Tier I/II mutations were identified in 90% (56/62) of cases. Consid...